Back to search

Peptide record

TPDB15324

Magainin A Antibacterial Anticancer standard
23 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB15324
Magainin A
Antibacterial Anticancer
Anti-infective peptides Cancer-related peptides
dbAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF
standard
No
A 23-aa standard natural multi-activity (Antibacterial and Anticancer) peptide sequence curated from dbAMP, Peptipedia, AntiCP 2.0, and other sources, with an available 3D structural model.
C-terminal: Amidation N-terminal: Beta-alanine
Sequence
AIGKFLHSAKKFGKAFVGEIMNS-NH2
Physicochemical Analysis
C115H182N30O29S1
RDCQPTWY
K
2480.95
10.55
5
1
11
+3
2.41
0.178
76.52
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
3
Residue Composition
number
3
A
0
R
1
N
0
D
0
C
1
E
0
Q
3
G
1
H
2
I
1
L
4
K
1
M
3
F
0
P
2
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 3 R: 0 N: 1 D: 0 C: 0 E: 1 Q: 0 G: 3 H: 1 I: 2 L: 1 K: 4 M: 1 F: 3 P: 0 S: 2 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
23
C115H182N30O29S1
2480.95
10.55
+3
2.41
0.178
Amidation
L
Linear
Beta-alanine
Antibacterial
African clawed frog Xenopus laevis skin Xenopus laevis
Evidence Records 16 records
Evidence 1 Activity

Activity

IC50
IC50=7.28 µM
Anticancer
7.28 µM

Target

Lung Cancer
NCI-H182
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1992

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=11.7 µM
Anticancer
11.7 µM

Target

Lung Cancer
NCI-H526
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1992
Evidence 3 Activity

Activity

IC50
IC50=6.23 µM
Anticancer
6.23 µM

Target

Lung Cancer
NCI-H678
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1992
Evidence 4 Activity

Activity

IC50
IC50=10.4 µM
Anticancer
10.4 µM

Target

Lung Cancer
NCI-H735
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1992
Evidence 5 Activity

Activity

IC50
IC50=9.7 µM
Anticancer
9.7 µM

Target

Lung Cancer
NCI-H841
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1992
Evidence 6 Activity

Activity

IC50
IC50=6.56 µM
Anticancer
6.56 µM

Target

Lung Cancer
NCI-H889
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1992
Evidence 7 Activity

Activity

IC50
IC50=16 µg/ml
Anticancer
16 µg/mL

Target

Lymphoma Cancer
U-937
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 8 Activity

Activity

IC50
IC50=18 µg/ml
Anticancer
18 µg/mL

Target

Leukemia Cancer
8402
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 9 Activity

Activity

IC50
IC50=23 µg/ml
Anticancer
23 µg/mL

Target

Hematopoietic Cancer
SSKT-1
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 10 Activity

Activity

IC50
IC50=30 µg/ml
Anticancer
30 µg/mL

Target

Lung Cancer
Daudi
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 11 Activity

Activity

IC50
IC50=34 µg/ml
Anticancer
34 µg/mL

Target

Leukemia Cancer
MLA
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 12 Activity

Activity

IC50
IC50=20 µg/ml
Anticancer
20 µg/mL

Target

Lymphoma Cancer
Raji
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 13 Activity

Activity

IC50
IC50=40 µg/ml
Anticancer
40 µg/mL

Target

Leukemia Cancer
K-562
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 14 Activity

Activity

IC50
IC50=45 µg/ml
Anticancer
45 µg/mL

Target

Ewing sarcoma
CHP-100
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 15 Activity

Activity

IC50
IC50=49 µg/ml
Anticancer
49 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 16 Activity

Activity

IC50
IC50=53 µg/ml
Anticancer
53 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990